TY - JOUR
T1 - Peripheral T‐cell lymphoma in childhood and adolescence a clinicopathologic study of 22 patients
AU - Gordon, Bruce G.
AU - Weisenburger, Dennis D.
AU - Warkentin, Phyllis I.
AU - Anderson, James
AU - Sanger, W. G.
AU - Bast, Martin
AU - Gnarra, D.
AU - Vose, Julie M.
AU - Bierman, Phillip J.
AU - Armitage, James O.
AU - Coccia, P. F.
PY - 1993/1/1
Y1 - 1993/1/1
N2 - Background. Peripheral T‐cell lymphoma (PTCL), although the most common T‐cell lymphoma in adults, is relatively rare in childhood, and only small series have been reported. Methods/Results. Twenty‐two cases of PTCL were studied that occurred in patients 18 months to 20 years of age. Nine were seen when the condition was diagnosed, and the other 13 were referred after they had relapses. The stage at diagnosis was I or II (45%), III (41%), and IV (14%). Patients with Stage IV disease were younger than those with Stage I or II disease (2.5 versus 14.8 years, P = 0.04). Twelve patients had extranodal disease when the diagnosis was made; the skin was the most common site. Ten tumors were classified as diffuse large cell type; five, as diffuse anaplastic large cell type; and seven, as diffuse mixed cell type. Twenty of the 21 tumors tested were CD30 (Ki‐1 or Ber‐H2) antigen positive. Of the nine patients seen when the diagnosis was made and treated by the authors, three had a relapse (median, 12 months), a 2‐year relapse‐free survival (RFS) rate of 61%. For the total group, the RFS was longer for patients older than 12 years of age compared with those who were younger (20 versus 12 months, P = 0.05). Overall, six patients remained in their first complete remission. Sixteen patients had a relapse, and 13 of these underwent bone marrow transplantation (BMT). Six of these remained in complete remission (median, 18 months after BMT). Overall, only 6 of 22 patients died (median survival, > 60 months). Conclusion. It was concluded that aggressive therapy, including BMT for relapses, can provide prolonged disease control in most children with PTCL. Cancer 1993; 71:257‐63.
AB - Background. Peripheral T‐cell lymphoma (PTCL), although the most common T‐cell lymphoma in adults, is relatively rare in childhood, and only small series have been reported. Methods/Results. Twenty‐two cases of PTCL were studied that occurred in patients 18 months to 20 years of age. Nine were seen when the condition was diagnosed, and the other 13 were referred after they had relapses. The stage at diagnosis was I or II (45%), III (41%), and IV (14%). Patients with Stage IV disease were younger than those with Stage I or II disease (2.5 versus 14.8 years, P = 0.04). Twelve patients had extranodal disease when the diagnosis was made; the skin was the most common site. Ten tumors were classified as diffuse large cell type; five, as diffuse anaplastic large cell type; and seven, as diffuse mixed cell type. Twenty of the 21 tumors tested were CD30 (Ki‐1 or Ber‐H2) antigen positive. Of the nine patients seen when the diagnosis was made and treated by the authors, three had a relapse (median, 12 months), a 2‐year relapse‐free survival (RFS) rate of 61%. For the total group, the RFS was longer for patients older than 12 years of age compared with those who were younger (20 versus 12 months, P = 0.05). Overall, six patients remained in their first complete remission. Sixteen patients had a relapse, and 13 of these underwent bone marrow transplantation (BMT). Six of these remained in complete remission (median, 18 months after BMT). Overall, only 6 of 22 patients died (median survival, > 60 months). Conclusion. It was concluded that aggressive therapy, including BMT for relapses, can provide prolonged disease control in most children with PTCL. Cancer 1993; 71:257‐63.
KW - Ki‐1 lymphoma
KW - adolescence
KW - childhood
KW - peripheral T‐cell lymphoma
UR - http://www.scopus.com/inward/record.url?scp=0027398324&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027398324&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19930101)71:1<257::AID-CNCR2820710139>3.0.CO;2-B
DO - 10.1002/1097-0142(19930101)71:1<257::AID-CNCR2820710139>3.0.CO;2-B
M3 - Article
C2 - 8380117
AN - SCOPUS:0027398324
SN - 0008-543X
VL - 71
SP - 257
EP - 263
JO - Cancer
JF - Cancer
IS - 1
ER -